Literature DB >> 22726344

Intestinal permeability and complications in liver cirrhosis: A prospective cohort study.

Jaya Benjamin1, Vikas Singla, Indu Arora, Seema Sood, Yogendra Kumar Joshi.   

Abstract

AIM: Increased intestinal permeability (IP) has been implicated as an important factor for bacterial translocation (BT), leading to bacteremia and endotoxemia, resulting in various septic complications, variceal bleeding (VB), hepatic encephalopathy (HE), hepatorenal syndrome (HRS) and death in patients with liver cirrhosis (LC). This study was planned to assess IP in patients with LC and follow them for the occurrence of complications.
METHODS: Patients with Child B and C cirrhosis without a history of disease-related complications were followed up for 6 months. IP was measured by lactulose and mannitol excretion ratio (LMR) in patients and 50 healthy controls (HC). Serum endotoxin levels were also assessed in 48 patients and 20 HC.
RESULTS: Eighty patients (74 male), 41 (51.3%) Child B and 56 (70%) Child C, with a mean age of 40.7 ± 9.8 years were enrolled. IP was increased in 28 (35%) patients. LMR of patients was higher than HC (patients vs HC = 0.0238 [0.0010-1.557] vs 0.0166 [0.0018-0.720]; P = 0.007]. No significant difference was seen in the LMR of patients among various Child classes and etiologies. Serum endotoxin levels (GMU/mL) were higher in patients than HC (patients vs HC = 1.42 [0.68-2.13] vs 0.994 [0.067-1.382]; P = 0.001), but comparable between patients with abnormal and normal IP. At follow up, there was no significant difference in the incidence of complications like spontaneous bacterial peritonitis, HRS, VB, HE and death between patients with abnormal and normal IP.
CONCLUSION: IP was increased in 35% of patients with LC; however, it was not associated with a higher incidence of disease-related complications.
© 2012 The Japan Society of Hepatology.

Entities:  

Year:  2012        PMID: 22726344     DOI: 10.1111/j.1872-034X.2012.01054.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  12 in total

Review 1.  Gastrointestinal dysfunction in liver cirrhosis.

Authors:  Evangelos Kalaitzakis
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 2.  Risk factors and outcome of bacterial infections in cirrhosis.

Authors:  Tony Bruns; Henning W Zimmermann; Andreas Stallmach
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

3.  Dual-sugar tests of small intestinal permeability are poor predictors of bacterial infections and mortality in cirrhosis: A prospective study.

Authors:  Anika Vogt; Philipp A Reuken; Sven Stengel; Andreas Stallmach; Tony Bruns
Journal:  World J Gastroenterol       Date:  2016-03-21       Impact factor: 5.742

Review 4.  Changes of Intestinal Functions in Liver Cirrhosis.

Authors:  Hiroshi Fukui; Reiner Wiest
Journal:  Inflamm Intest Dis       Date:  2016-03-08

5.  Fecal microbiota transplantation prevents hepatic encephalopathy in rats with carbon tetrachloride-induced acute hepatic dysfunction.

Authors:  Wei-Wei Wang; Yu Zhang; Xiao-Bing Huang; Nan You; Lu Zheng; Jing Li
Journal:  World J Gastroenterol       Date:  2017-10-14       Impact factor: 5.742

6.  Effect of liver transplantation on intestinal permeability and correlation with infection episodes.

Authors:  Francesca Romana Ponziani; Venanzio Valenza; Erida Nure; Giuseppe Bianco; Giuseppe Marrone; Antonio Grieco; Maurizio Pompili; Antonio Gasbarrini; Salvatore Agnes; Gabriele Sganga
Journal:  PLoS One       Date:  2020-06-26       Impact factor: 3.240

Review 7.  Non-alcoholic fatty liver disease, diet and gut microbiota.

Authors:  Carmine Finelli; Giovanni Tarantino
Journal:  EXCLI J       Date:  2014-05-07       Impact factor: 4.068

8.  Taurocholic acid is an active promoting factor, not just a biomarker of progression of liver cirrhosis: evidence from a human metabolomic study and in vitro experiments.

Authors:  Zhimin Liu; Zhifeng Zhang; Mei Huang; Xiaoping Sun; Bojia Liu; Qiyang Guo; Qingshan Chang; Zhijun Duan
Journal:  BMC Gastroenterol       Date:  2018-07-11       Impact factor: 3.067

Review 9.  Management of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directions.

Authors:  Elda Righi
Journal:  World J Gastroenterol       Date:  2018-10-14       Impact factor: 5.742

10.  Rifaximin has the potential to prevent complications of cirrhosis.

Authors:  Steven L Flamm; Kevin D Mullen; Zeev Heimanson; Arun J Sanyal
Journal:  Therap Adv Gastroenterol       Date:  2018-09-28       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.